HENRY SCHEIN INC (HSIC) Q2 2026 Earnings Call Transcript

Good morning, ladies and gentlemen, and welcome to Henry Schein's Second Quarter 2026 Earnings Conference Call. As a reminder, this call is being recorded. I would now like to introduce your host for today's call, Graham Stanley, Henry Schein's Vice President of Investor Relations and Strategic Financial Project Officer. Please go ahead, Graham.

Thank you, operator, and my thanks to each of you for joining us to discuss Henry Schein's financial results for the second quarter of 2026. With me on today's call are Fred Lowery, Chief Executive Officer; and Ron South, Senior Vice President and Chief Financial Officer. Before we begin, I'd like to state that certain comments made during this call will include information that is forward-looking. Risks and uncertainties involved in the company's business may affect the matters referred to in forward-looking statements, and the company's performance may materially differ from those expressed in or indicated by such statements. These forward-looking statements are qualified in their entirety by the cautionary statements contained in Henry Schein's filings with the Securities and Exchange Commission and included in the Risk Factors section of those filings. In addition, all comments about the markets we serve, including end market growth rates and market share, are based upon the company's internal analysis and estimates. Today's remarks will include both GAAP and non-GAAP financial results. We believe the non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable the comparison of financial results between periods where certain items may vary independently of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding GAAP measures. Reconciliations between GAAP and non-GAAP measures are included in Exhibit B of today's press release and can be found in the Financials and Filings section of our Investor Relations website under the Supplemental Information heading and also in our quarterly earnings presentation also posted on our Investor Relations website. The content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, August 4, 2026. Henry Schein undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Lastly, during today's Q&A session, please limit yourself to a single question so that we can accommodate questions for as many as you as possible. And with that, I'd like to turn the call over to Fred Lowery.

Thank you, Graham. Good morning, everyone, and thank you for joining us. I'm very excited to share our results with you today, so let's dive right in. We delivered strong sales performance and margin improvement in the second quarter, driven by sustained momentum across our businesses and solid operational execution by the team. Internal local currency sales growth accelerated compared to the first quarter. This acceleration, combined with the strong gross margins and the early benefits from value creation initiatives drove strong earnings growth. Our first half performance and the sustained momentum have positioned us to raise our full year 2026 guidance. Ron will provide more details later in the call. Before we get into more detail on the quarter, I want to share some feedback from various stakeholders I've met in my first month here at Henry Schein and also some of my thoughts on why I'm confident in our opportunities ahead to accelerate growth. Our customers value the range of products and the integrated technology solutions we offer to support the growing complexity of operating a health care practice. And they see Henry Schein as a reliable business partner due to our consistent execution, our product quality and our responsiveness. Our supplier partners also recognize our deep customer relationships, and they want to do more business with us. And our growth helps ensure we remain their partner of choice. In addition to customers and suppliers, I spent a lot of time talking with employees and shareholders who are optimistic about our plans to improve, including making decisions faster, simplifying how we operate and executing more consistently for the benefit of our customers. Henry Schein has great assets and capabilities, and our customer reach is really unmatched. What's exciting is that after my first few months at the company, I have an increased conviction that there is significant opportunity to improve our revenue growth and improve our profitability and ultimately become the platform to help health care practitioners operate a better practice. So as we sharpen our focus, our priorities ahead are accelerating growth, simplifying our business, driving operational rigor and further deepening our customer relationships, all of which we believe will create sustainable shareholder value. With respect to accelerating growth, we're already pursuing several key initiatives to do more for our customers, and these initiatives are beginning to pay off. For example, we're advancing our Henry Schein One technology platforms, including AI-enabled solutions to improve workflows and collections, enhance practice performance and strengthen patient engagement. This functionality is embedded in our Dentrix Ascend and our data shows that customers who convert to Dentrix Ascend are seeing a clear improvement in their profitability. June was a record month for the number of new Dentrix Ascend customers, growing both our customer base and capturing share of wallet. While our average monthly revenue per customer for Henry Schein One is approximately $500, our average monthly revenue for Dentrix Ascend customers is approximately $800, and is growing as customers recognize the value of the new integrated capabilities and upgrade to higher levels of functionality. We're also accelerating our sales in our own brand products, including our corporate brands by leveraging our One Schein approach and aligning our go-to-market strategies across the business. For example, in endodontics, our Edge brand, which we started distributing through our U.S. dental distribution business last year has very strong sales growth. We also have a leading position in the fast-growing DSO segment of the market, which is driven especially by the middle market segment. As these DSOs continue to consolidate the dental market, this structural advantage should allow us to outgrow the broader dental market. And finally, we've expanded our medical business to attractive high-growth areas, including our Home Solutions business, which grew sales in the high single digits last quarter. To simplify our business, we're taking an integrated versus a decentralized approach across several areas. For example, we are implementing shared service back-office functions globally and centralizing our indirect procurement. We also need to make it easier for us to work with each other as well as for our customers to work with us. So we're eliminating internal silos and aligning individual incentives with broader company-wide goals. We're also evaluating our portfolio with a focus on businesses that drive higher growth and higher returns. Finally, we're driving operational rigor by delivering what we expect to be at least $200 million in operating income improvements from value creation initiatives over the next few years. But this is not just about the $200 million. It's about creating a high-performance culture of accountability and continuous improvement while also increasing customer satisfaction. Complementing these efforts is a deliberate approach to capital deployment to ensure that resources are allocated to maximize long-term value. Across all of these efforts, a relentless focus on customer success will guide how we prioritize and how we execute. By helping customers operate more efficiently, making better decisions and deliver better care, we can strengthen our relationships and further enhance our competitive position. As a result, we expect to accelerate growth and expand our market share, deliver stronger financial performance and create durable shareholder value. With disciplined execution and working smarter as one team, we expect to deliver a better customer experience and a more profitable business. Now let's turn to the second quarter results. Our markets remain stable and durable and have good underlying fundamentals and a long runway for growth. We're not seeing a significant impact on patient volumes resulting from higher oil prices, and we believe the markets we serve are resilient to economic pressure. Our dental merchandise business was strong globally, and we made further gains in market share in the quarter. Our U.S. dental merchandise sales performance continued to outpace the market, led by our corporate brands and by our exclusive products such as Curodont. With our unique product offering, along with new sales reps, we are expanding our share of wallet and converting occasional buyers to actively engaged customers. Merchandise sales growth also accelerated internationally with markets like Canada standing out. In Canada, we continue to take market share. Our advantage in Canada goes well beyond our portfolio breadth, though. It's also our best-in-class technology service, our ability to attract top talent and the depth of our customer relationships that really differentiates us there. The U.S. Dental Equipment sales remain on pace for the quarter given the tough comparable from U.S. dental school orders in the second quarter of last year. We continue to drive sales growth from our exclusive supplier sponsored promotions and our backlog remains healthy, and we expect U.S. equipment growth for the rest of the year. International equipment growth was broad-based and continues to be good. The non-acute care U.S. medical market remains solid, and our government-related and Home Solutions businesses continue to grow well. Despite lower demand for point-of-care diagnostic tests, our medical business saw good underlying growth. Our specialty product sales were also solid in the quarter. Overall, implant growth in Europe was high single digits with premium implants led by our Camlog brand, which is the market leader in Central Europe and value implants led by our Biotech Dental and Medentis brands. We achieved more modest growth in the U.S. where our Tapered Pro Conical implant drove positive results as well as our S.I.N. 360 which was recently launched in the U.S. Finally, sales growth in endodontic products was also good in aggregate across all of our businesses. Our global technology business, Henry Schein One, delivered another quarter of strong growth with sustained momentum in cloud-based software and technology solutions. Almost 13,000 customers now subscribe to our Dentrix Ascend and Dentally cloud-based platforms. And we're seeing more customers move toward our higher featured packages, which is increasing our monthly revenue per customer. Additionally, approximately 90% of Henry Schein One's revenue is recurring. This creates a highly predictable business model. By leveraging the data from our market-leading practice management system, we are now broadly embedding AI tools in our software for which our customers are recognizing meaningful benefits. The recent launch of our next-generation AI clinical workflow has been met with strong market reception, reinforcing Henry Schein's position at the forefront of the industry's AI transformation. Some examples include our voice-enabled clinical note documentation, our patient insurance eligibility analysis, claims and collection management as well as clinical diagnosis and treatment analysis. These new capabilities help to drive productivity for private practice, for group practices and for DSOs. As dental practice labor costs continue to rise, our customers are looking to Henry Schein to help them operate more efficiently. These technology solutions uniquely position us to address this growing need. A few weeks ago, I spent some time with our Henry Schein One team in Utah. And while I'm excited about the capabilities that we've recently launched and even more confident in the opportunities that are ahead. Henry Schein One's vision includes expanding AI deeper into the clinical and operational workflows through additional capabilities. So I'll make one quick announcement. Coming soon is the launch of an MCP layer that enables practices to query their own data with AI applications and agents. This allows them to identify revenue opportunities as well as to drive further operational efficiencies in a targeted manner. Now I'll highlight the progress that we've made advancing our strategic plan during the quarter. Our overall margins expanded, partially driven by our high-growth, high-margin businesses, which now represent almost 50% of total operating income. We remain on track to exceed our goal of over 50% by the end of our strategic planning cycle in 2027. Additionally, our own brands, including our corporate brands, continue to grow well at almost twice the rate of other merchandise sales. Our value creation plans remain a top focus for our team, and we are on track to achieve our goals. I'd like to go a click deeper and share some of the key initiatives supporting these value creation plans. First, we've selected our global outsourcing provider to support finance and customer service and have begun implementing Phase 1 within our U.S. businesses. We expect to see initial benefits from labor cost efficiencies starting in the third quarter, and we expect this project alone to deliver more than half of the G&A savings in our $200 million goal. Second, we've set up a procurement office to identify preferred suppliers and consolidate indirect spend across our businesses. This is already yielding results for us. And third, we've started to use our sales data to identify margin opportunities, enabling more dynamic and disciplined pricing, which is helping us expand our gross profits. As we look towards next year, we're planning to implement several new initiatives, including broadening the scope of our outsourcing initiative, expanding our AI capabilities to drive productivity and implementing new supply chain software to improve efficiencies, reduce inventory and streamline our purchasing processes. Each of these products should contribute to additional savings and help us progress toward our goal of double-digit earnings growth next year. I'm encouraged that our momentum continued in the second quarter, and I'm incredibly excited as we transform into the value creation platform for our customers. With that, I'll now turn to Ron to review in more detail our second quarter results and our full year 2026 guidance. Ron?

Thank you, Fred, and good morning, everyone. Today, I will review the financial highlights for the second quarter. We were encouraged by the underlying strength across the business as demonstrated by some key financial metrics for the quarter, including strong internal local currency sales growth of 4.6%, non-GAAP operating income growth of 10.5% and non-GAAP earnings per share growth of 15.5%. Starting with our second quarter sales results. Global sales were $3.5 billion, with sales growth of 6.7% compared with the second quarter of 2025. This reflects internal local currency sales growth of 4.6%, a 1.4% increase resulting from foreign currency exchange and 0.7% sales growth from acquisitions. Our GAAP operating margin for the second quarter of 2026 was 4.94%, an increase of 27 basis points compared to the prior year GAAP operating margin. On a non-GAAP basis, the operating margin for the second quarter was 7.21%, up 25 basis points compared to the prior year, driven by gross margin expansion in all segments. Second quarter 2026 GAAP net income was $94 million or $0.82 per diluted share. This compares with prior year GAAP net income of $86 million or $0.70 per diluted share. Our second quarter 2026 non-GAAP net income was $145 million or $1.27 per diluted share. This compares with prior year non-GAAP net income of $135 million or $1.10 per diluted share. Foreign currency exchange favorably impacted our second quarter diluted EPS by approximately $0.01 versus the prior year. We did not record any remeasurement gains in the second quarter of 2026. This compares with a remeasurement gain of $3.6 million in the second quarter of 2025. Finally, adjusted EBITDA for the second quarter of 2026 was $288 million compared with second quarter 2025 adjusted EBITDA of $256 million or 12.7% growth. Turning to our sales results. The components of sales growth for the second quarter are included in Exhibit A in this morning's earnings release. I will now provide the primary highlights of the main sales drivers for each reporting segment. Global Distribution and Value-Added Services group sales grew by 6.6%, reflecting good sales momentum across most regions. Looking at the components of that growth, U.S. Dental Merchandise sales grew 8.3% with 6.5% internal local currency sales growth, resulting from a combination of pricing and increased volume. Our U.S. Dental Merchandise sales growth continues to accelerate. We believe patient traffic remained stable throughout the quarter and that we achieved market share gains. U.S. Dental Equipment sales declined 1.1%, primarily due to lower traditional equipment sales growth, which was negatively impacted by a few large dental school orders last year. We did experience modest growth in our digital equipment category and expect U.S. Dental Equipment growth for the rest of this year. U.S. Medical Distribution sales grew 3.8% despite continued headwinds in point-of-care diagnostic product sales. We were especially pleased with the growth in our government-related businesses and our Home Solutions business. International Dental Merchandise sales grew 11.1% with 5.4% internal local currency sales growth, driven by sales growth in Canada, France, Brazil and Australia. International Dental Equipment sales grew 8.7% with internal local currency sales growth of 5.4%. We achieved good sales growth in traditional equipment with modest growth in the digital equipment category. Equipment sales growth was especially good in Canada, Germany, Spain and the U.K. Finally, global value-added services sales grew 5.1% with 3.7% internal local currency sales growth, driven by our business solutions services in both the U.S. and internationally, partially offset by lower financial service revenues in the U.S. Turning to the Global Specialty Products Group. Sales grew 8.7% with 3.2% internal local currency sales growth. Sales growth was driven by implants and biomaterials in both our premium and value products. Premium implant sales growth continues to be strong in Europe and grew modestly in the U.S. Value implant sales growth was driven by S.I.N. 360 in the U.S. and by our European brands. Our Global Technology Group also posted good results with total sales growth of 8.2% with 9.1% internal local currency sales growth. In the U.S., we continue to have strong revenue growth in our Dentrix Ascend practice management business. Internationally, sales growth was driven by our Dentally cloud-based practice management software product. Regarding restructuring costs, the company recorded restructuring expenses of $29 million or $0.18 per diluted share during the second quarter of 2026 as we continue to advance our value creation initiatives. We continue to expect to achieve our goal of achieving greater than $200 million of operating income improvement resulting from our value creation initiatives with a $125 million run rate by the end of 2026 and for these projects to continue into the early part of 2028, providing us confidence as we progress toward our goal of double-digit earnings growth. Regarding the operating income improvements in 2026 from our value creation initiatives, we expect approximately 40% of the in-year operating income improvement to originate from the gross profit initiatives and 60% from G&A expense savings. Beyond 2026, the benefits are expected to be more heavily weighted to G&A savings. Regarding share repurchases, during the second quarter of 2026, the company repurchased approximately 2.6 million shares of common stock at an average price of $76.69 per share for a total of $200 million. At the end of the quarter, we had approximately $455 million authorized and available for future stock repurchases. Turning to our cash flow. We generated strong operating cash flow of $242 million in the second quarter of 2026, driven by higher net income and working capital management. Operating cash flow remains on track to exceed net income for the full year. Turning to our 2026 financial guidance. At this time, we are not able to provide without unreasonable effort, an estimate of restructuring costs, including those related to ongoing value creation initiatives. Therefore, we are not providing GAAP guidance. Our 2026 guidance is for current continuing operations and does not include the impact of restructuring expenses and related costs and other items described in our press release. Guidance does not include any remeasurement gains for the remainder of 2026 or any future benefits from tariff refunds. Note that total remeasurement gains in fiscal year 2025 were $38 million. And in 2026, we expect total remeasurement gains of $11 million, which was already recorded in the first quarter. Our guidance also assumes that foreign currency exchange rates will remain generally consistent with current levels. Our 2026 total sales growth is now expected to be in the range of 4.5% to 5.5% over 2025 compared to our previous guidance of 3% to 5%. This reflects approximately 3.5% to 4.5% of expected internal local currency sales growth in the second half of the year versus actual internal local currency sales growth of 3.6% in the first half of the year despite a higher prior year comparison in the second half of the year. For 2026, we now expect non-GAAP diluted EPS attributable to Henry Schein, Inc. to be in the range of $5.29 to $5.39, reflecting growth of 6% to 8% compared to 2025 non-GAAP diluted EPS of $4.97. Our prior guidance was a range of $5.23 to $5.37. This raise in guidance reflects stronger underlying expected sales performance, partially offset by lower remeasurement gains than originally anticipated. Our value creation projects remain on track, and the benefits for the year are unchanged from prior guidance. We expect earnings growth in the fourth quarter to exceed that in the third quarter, reflecting continuing sales momentum and increasing benefits from value creation projects. In addition, as a reminder, we recorded a $28 million remeasurement gain in the third quarter of 2025, which will not recur in 2026. Regarding taxes, we are assuming an estimated non-GAAP effective tax rate of approximately 24% for the full year, and our 2026 adjusted EBITDA is expected to grow in the mid- to high single digits off a base of 2025 adjusted EBITDA of $1.1 billion. So with that overview of our business and recent financial results, we're ready to take questions. Operator?

And our first question is from the line of Jeff Johnson with Baird.

Congratulations on a very solid quarter here. So Fred, I wanted to talk just on the U.S. dental consumables market and your performance expectations going forward. I think through the first half of the year you're just over 4%. Maybe help us understand how much of that you believe is underlying volume growth versus a combination of price and whether you're seeing any increased mix from some of your manufacturers. First, what are the components of that growth from a high level, I'm sure you don't want to break it down in great detail. But then as you comp into tougher comparisons in the second half on the U.S. consumables side, how should we think conceptually about that 4% or just north of 4% you put up in the first half? Can we stay around that number against those tougher comps? Or conceptually, how would you set us up, maybe help us set up our models as we go into the back half of the year?

Yes, Jeff, thanks for the question. As I think about consumable and merchandise growth, first off, we're excited about the growth we're seeing. We're seeing a little more price than volume. We expect to continue to see a similar range of growth in the second half that we saw in the first half. Comps get a little more difficult, but we do expect to see that. What’s really driving it is this: last year we ran promotions starting in the second half where we targeted episodic customers or those not consistently buying from us. Those promotions worked and converted many of those customers into actively engaged buyers who continue to purchase. So we expect to continue to see that in the second half and for the growth rate to remain in the same range, aside from the impact of higher comps.

Our next question is from the line of Jason Bednar with Piper Sandler.

Congratulations on another good quarter, everyone. Ron, I want to ask about the value-creation math. I appreciated the additional color today on the mix of contributions. On the bigger picture, you're standing behind the $125 million run rate contribution to EBIT exiting this year. Simple math suggests roughly $35 million or more of year-over-year EBIT dollar growth before even considering organic growth, which is clearly strong. Yet consensus is modeling only about $10 million in EBIT growth in the second half. Maybe an odd question, but what do you think consensus is mis-modeling or misunderstanding, given that you are delivering good results and standing behind that value-creation commitment?

No, thanks for the question, Jason. As we look at the value creation initiatives, our guidance takes into account a range of potential outcomes, but we still believe we have a good path to achieve a run rate of $125 million of operating income improvements by the end of 2026. Many of those improvements will be realized later in the year, in Q3 and Q4. As Fred mentioned in the prepared remarks, we have engaged a third party to help with what we internally call global business services. We also have other initiatives gaining traction as we move into the second half of the year. All of that is reflected in our guidance, and we will provide more details on actual achievements when we report Q3 results. Keep in mind that if you look at year-over-year results, last year we had significant remeasurement gains in the second half, specifically a $28 million gain in Q3, which you need to normalize for. As we noted, our guidance assumes no further remeasurement gains for the rest of the year.

Our next question is from the line of Elizabeth Anderson with Evercore ISI.

Congrats on the quarter. I was wondering if you could give us a little bit more color on the 40% of cost savings that you said were coming from the gross margin line. Is that sort of split between the pricing initiatives and sort of better growth in sort of higher-margin areas? Anything else to consider there? And sort of maybe, Fred, one for you more broadly is like if we think about these specialty categories, what are some places where you see further opportunities to accelerate growth as we get into maybe '26 and beyond that?

Yes. On the first one, the 40%, you're exactly right. It includes our initiatives around improving our gross profit, leveraging data better to have a more dynamic view of our pricing—not dynamic pricing per se, but making pricing more dynamic—and finding opportunities to both raise price where it makes sense and lower price where it makes sense to drive more volume. Also, as I mentioned earlier, we're seeing really good growth from our corporate brands and our own brands, and that continues to drive our gross profit as well. Those are the two main drivers. On the second question around specialty, we're excited about the specialty business. One of the things we haven't talked a lot about is that our new specialty products are really exciting, so we expect greater growth in specialty, particularly in our implant business, as we took a majority stake in S.I.N. 360 in Q1 and are working to align that strategy. In the U.S., in particular, we’re seeing growth in the value segment, and we believe we have a very good offering there and will see further growth. We also have very leading brands in Europe and saw strong growth in the implant business there, so we're excited about the implant business and its future growth from a specialty standpoint.

Our next question is from the line of Allen Lutz with Bank of America.

I want to follow up on Elizabeth's question around the gross margin. Really nice expansion across all 3 segments, and you talked about 40% of the benefits you're seeing this year coming from gross profit. As we think about the second quarter results, how much of the gross margin expansion benefits are embedded in 2Q? And then should we expect more in 3Q, 4Q? Or is this the right run rate for the rest of 2026?

Allen, I think that we did see some margin benefit in the second quarter. As we mentioned in the prepared remarks, we're also seeing, for example, better growth in some of our own brands versus third-party brands, and those do carry better gross margins, and that starts to show itself there. I think as we continue to get some growth in specialty and the ongoing growth in the technology segment as well, those obviously are accretive to that overall margin. So within distribution, we're beginning to see some of the early benefits of the value creation initiative. I think we can build on that as we get into the second half of the year. There's always other factors that come into play in terms of mix. We will expect, for example, better equipment sales in the second half of the year. Equipment sales are typically at a lower margin than merchandise. But I think that as we progress in the year, we will continue to see, and I'll refer to it more as, gross profit improvements and gross profit benefits. Sometimes it doesn't always show up in margin percentage, but if it grows our gross profit dollars, we consider that to be what the primary goal is there.

The next question is from the line of Jonathan Block with Stifel.

Joe Federico on for John. Maybe just to clarify on the U.S. dental equipment. I know you had tough comps in the quarter due to the onetime dynamics last year. But you expect year-over-year growth throughout the remainder of the year on a quarterly basis, right? And then maybe just quickly, how are the trends between traditional and digital? We've obviously seen broadly some pressure on digital equipment. So if you can just rehash those dynamics in this quarter and then how you're seeing them play out to date in the second half, that would be great.

Yes. So I'll take the first part, and then I'll let Ron talk about the digital piece. But yes, yes, you're exactly right. We did have some tougher comps in Q2 we expect to see growth in the next 2 quarters in equipment. Our bookings look strong, and we feel good about seeing that business grow in the second half of the year. So just on the split between digital and non-digital, I'll let Ron take that.

Yes, certainly. So Joe, I think as you're aware, our equipment business is roughly two-thirds traditional equipment and about one-third digital. In the U.S., we saw low single-digit growth in digital in the quarter. And that's despite some ongoing lower average selling prices, for example with scanners. We're seeing good volume growth on scanners, so we did get some scanner growth even though demand for scanners tends toward the lower-priced entries in the market rather than some of the higher-priced scanners available. So digital delivered modest growth, and I think we can continue that modest growth going forward. And as Fred said, on the traditional side, the backlog gives us really good visibility into what we think we can accomplish in the balance of the year, hence our expectation that equipment will grow for the rest of the year.

The next question is from the line of John Stansel with JPMorgan.

Great. I just want to drill in on specialty margins expanded nicely year-over-year. I think in previous quarters, we've discussed the idea that value implants outgrowing premium implants creates a bit of a margin headwind. Is it fair to say that reversed this quarter? Or how are we thinking about the mix contribution from premium versus value in this quarter and then the durability of that going forward?

John, yes, I'll take that one. I think that the margin expansion is an indication of the strength of the premium implants business in Europe right now. We get very good margins on our revenues there, and we did see very good growth. The premium implant growth in the U.S. was a little more modest, but in Europe, it was quite good. Having said that, we're pleased with the value implant growth in the U.S. as we continue to get some traction and introduce the S.I.N. 360 value implant within the U.S. But I would say the mix had a bit of a shift given the strength of the premium implant business in Europe. We also saw kind of across the board good margins on endodontics and a few other products within that segment as well.

The next question is from the line of Kevin Caliendo with UBS.

Congrats on a really good quarter. I'm interested, you're talking about specialty in Europe. There's been some questions on it. But the dynamics there, we also saw this from another specialty player where EMEA was strong and international was strong and the U.S. wasn't. Is this a reflection of Henry Schein's products and specifically? Or is there something going on in the U.S. market? Is it more just consumer-driven versus EU? I'm just trying to understand why the strength exists in EU and not in the Americas right now for specialty.

Yes. I think it's a market issue, a market difference in the U.S. versus in EMEA. And so I think the market in the U.S. is more consumer like as it relates to implants relative to what you see in EMEA. So we believe we took share in the U.S. market, but in the quarter, that is for our premium implants and frankly, for implants in general. But the market is just not growing as fast in the U.S. as it is in EMEA.

Our next question is from the line of Glen Santangelo with Barclays.

I just wanted to come back to this faster-than-expected sort of consumable number. In your prepared remarks, I think you sort of suggested that patient volumes continue to be stable, but the better growth was really coming from market share gains. And I was wondering if you could elaborate on that a little bit and give us maybe a better sense for where the market share is coming from. And then, Ron, as you sort of look at the quarterly results, is there any story to tell intra-quarter between like April, May and June? Or was the growth pretty ratable throughout the quarter?

Yes. I think the share gain is coming from a couple of places. First, our own brands continue to grow faster than our third-party brands, so we're gaining share there. Second, we have a strong position with DSOs and structurally DSOs are growing faster than the rest of the market, which supports our growth rate. Third, as I mentioned earlier, we are converting customers from episodic buyers into consistent, active buyers, and we are seeing growth from that. Finally, some of our exclusive products, such as Curodont, are seeing good growth. Those factors together allowed us in the quarter to outpace the market, and we expect that to continue.

Yes. And Glen, regarding the second half of your question, I would say in the second quarter we saw what I would consider to be a fairly steady, consistent pattern over the course of the quarter. The second quarter tends to be, at least within the quarter, a little more predictable than perhaps the first quarter, where you might have weather or illness disruptions within the market. The second quarter was pretty steady. I would say we felt like we had a good, strong finish to the quarter, which is always encouraging. But for the most part, it was a fairly steady quarter, April, May to June.

The next question is from the line of Brandon Vazquez with William Blair.

Congrats on a nice quarter. Maybe I'll focus on 2 kind of broader high-level questions because a lot of near-term things have been asked. Fred, as you had mentioned portfolio. I'm not sure portfolio rationalization or optimization was the exact phrase you used, but maybe spend a second talking to us about what exactly that means? What are you looking for within the portfolio that should or should not be there? And then the higher-level question to follow up on that is just, Fred, as you look at this organization, not in 1 year, but like 3 years out, what do you think the biggest differences investors should expect given a lot of the changes that are going now, both from an operational and a commercial perspective?

Yes. Thanks for the question. As it relates to the portfolio, we're obviously taking a look at the portfolio. I don't expect major changes to the portfolio. But as we've laid out, our priorities are really focused around accelerating growth and driving better returns. We're looking for places in the portfolio that don't line up with that. Will there be some pruning to the portfolio? We'll see, and we'll let you know what we find going forward. Secondly, I'll extend that to our thinking on M&A. I think you'll see us be very disciplined from an M&A perspective and focus on things that are highly strategic, meaning things that help us continue to build this platform for value creation for our customers. So things that we will be the natural owner of or the rightful owner of in order to support our customers better and things that are going to help us grow faster and deliver great returns to our shareholders. That's how I'm thinking about the portfolio. As we make decisions around that, we'll get back to you. Looking a few years out, we're going to deliver on our commitments in the short term. But longer term, we expect to see this business accelerate growth and do it more profitably. Ultimately, we want to be positioned less as a distributor, though we will be a great distributor for our customers, and more as the practice improvement platform for our customers, where we help them optimize their businesses, grow faster and do it more productively. We're focused on helping our customers improve their situation. If we do that well, we should be able to reach our goals of accelerating growth and doing it more profitably.

Our next question is from the line of David Larsen with BTIG.

Congratulations on the strong growth you delivered. Can you talk a little more about the AI efforts, Dentrix, the software, and the technology? You mentioned you're going to create an analyzer solution. How many of your Dentrix customers buy merchandise through you and consider you their core distributor? What is the growth potential there? All of that sounds very important to me because your dentists can accelerate their volume growth, which benefits both you and them. Any additional color would be very helpful.

Yes. Thanks for the question. I appreciate your excitement about it because I'm super excited about our technology business as well. Let me start with the AI piece. The thing that's really exciting is not just the capabilities that we're launching, the AI capabilities that we're launching into our PMS platforms, but it's also the fact that we're using AI to develop those capabilities. And so we're able to bring new capabilities to market faster. And that, I think, will continue to help us accelerate our growth. As we add capabilities to the PMS systems, our customers are recognizing the utility and the benefit and they're moving up to higher order packages, so we're getting share of wallet gains, and we're also getting share of market gains by adding more customers to our cloud-based PMS. So that's quite exciting. The second part that you mentioned is what's the connection between customers that are buying merchandise from us or buying products from us and using our PMS system. And we haven't really connected those dots publicly. But what I would say to you is that is a real opportunity for us to make sure that it's easier for customers to do business with us. And if you have our PMS system, it makes a lot of sense for you to buy all of your merchandise from us. And that is part of the customer value proposition to us being the practice improvement platform for our customers. So we're excited about continuing to see that happen and helping to allow that 90% of recurring revenue from our PMS system to help to drive the rest of our business as well.

The next question is from the line of Michael Sarcone with Jefferies.

I guess the company just put out a press release on some changes to the executive management committee and the new Henry Schein leadership team. I was wondering if you could kind of unpack that a little bit and elaborate on some of the changes you're making and what you hope to accomplish there.

Yes. Thanks for the question. We announced some changes to the leadership team really with a goal of doing a couple of things. One is just getting closer to customers and being able to increase the speed at which we make decisions and to increase our pace and frankly, improve our execution consistency. So what that really looks like is that we removed the layer, which puts me a little closer to the business. We integrated our supply chain more deeply into our distribution business, which puts us closer to the customer. And I think you'll see that continue to increase our executional capability. I do want to just take a moment and just thank Michael and Mark and Jim, 3 long-serving executives here over 100 years of experience, and I am incredibly grateful for their contributions to the business. And I'm even more grateful that they've decided to stay on as senior advisers to me and to the leadership team in support of the company going forward. So I feel like we're in a really great place from a leadership team standpoint, and we'll continue to add the right capabilities to deliver on the opportunity set that's in front of us.

The next question is from the line of Steven Valiquette with Mizuho.

Just for the Specialty Products Group, you mentioned the profit growth in the segment was 19.9%, and some of that was organic versus inorganic. So apologies if I missed it, but I just wanted to get just the approximate breakdown within that specialty area, how much of that profit growth was organic versus inorganic?

Thanks for the question. I think that a significant majority of that is going to be organic. We did have an acquisition within the Specialty Group in the back half of 2025 that is contributing to some of that operating income growth, but a significant majority of that is organic. And I think that equally important, I think we had some improvements in the operating margins within that business as well. So some good efficiencies, we continue to make some operating changes within the Specialty Group, consolidating some operations, again, going to market more as a singular business as opposed to a portfolio approach, and we're beginning to see some of the benefits of those changes start to emerge in the financial results.

The next question comes from the line of Michael Cherny with Leerink Partners.

Maybe circling back to the value creation program. It's encouraging to hear that you're sticking on the opportunity cost cut side. How are you thinking about the flip side, though, and the potential to reinvest some of those savings? Obviously, I know you're targeting double-digit growth. But given we've heard so much about share gain opportunities here, what does it look like on the far side once you get to that $200 million run rate?

Yes. Listen, I think we actually call value creation internally "value creation for growth." We're absolutely committed to the $125 million run rate by the end of this year and to $200 million over a few years. But we're not going to stop there. We're going to continue to create space in the P&L so that we can invest in opportunities that help us accelerate growth. So I think what we've committed to are hard commitments, but we continue to work to optimize our business, and we'll make the appropriate investments to take advantage of the opportunity set from a growth standpoint.

Our next question is from the line of Vik Chopra with BMO.

Congrats on a nice quarter. I'll just keep it to one. So you raised your revenue guidance but only modestly increased the EPS guidance. Can you talk about the factors preventing the stronger earnings flow-through from the higher sales outlook, please?

From a sales perspective, we continue, as we said, to expect internal growth to be slightly better than the internal growth we had in the first half of the year. I do think we will not receive the same foreign exchange benefits we experienced in the first half of the year, and that has been taken into consideration in the overall revenue growth. From an EPS perspective, it reflects that improvement in sales, but it also reflects an adjustment to our expectations, for example around remeasurement gains. We are not expecting any further remeasurement gains in the balance of the year. That means the full year remeasurement gain benefit will be $11 million. Our original expectations were within a range, but that $11 million was very much toward the low end of that range. So that is reflected within our revised EPS guidance as well.

Our next question is from the line of Daniel Grosslight with Citi.

I'll focus a little bit on the Medical segment, the U.S. Medical segment. Fairly good growth despite the headwinds in point-of-care diagnostics. I was hoping you can provide maybe a little bit more detail on the size of that headwind and when you guys think that this should start to abate? And then on the strength you're seeing in the government-related and Home Solutions side of the business, I'm curious if you could kind of parse out or double-click on some of the areas of strength within those 2 segments.

Sure. I'll address that. I think in terms of the core medical business, the impact on revenues from the diagnostic products is less significant in the middle of the year, meaning Q2 and Q3, versus Q4 and Q1 when there's a greater rate of respiratory illness. Having said that, we did see lower demand in Q2 for those products this year versus last year. But we did get very good growth. You mentioned the Home Solutions business, and we did get very good growth there. That growth, as we mentioned in the prepared remarks, was approaching double digits; it was high single digits. I think that's really a function of continuing to gain traction as we expand available products and into different geographies from some of the acquisitions we've done on the Home Solutions side over the last couple of years, and we're starting to see some of the benefits of that. Those have been good investments for us. We do see greater growth in Home Solutions markets, and we also achieve that at better margins than in core medical markets. So that has been an area of focus and continues to be so.

The next question is from the line of Mike Petusky with Barrington Research.

Just one more time to go back to the value creation topic. I'm just wondering, I don't think I've heard you guys speak about this, perhaps I'm wrong, but I don't think I have. In terms of the sequencing by geography and some of these initiatives, whether it's pricing optimization, integrating M&A, labor cost efficiencies, sort of enhancing your technology. Can you just speak to if there is some meaningful sequencing of, hey, we need to go after this initiative in the U.S. first and then OUS, et cetera. I was just wondering if you could speak to that.

Yes. Thanks for the question. I don't know that I would use the regional lens. Obviously, we've sequenced our projects around what makes sense. It does just so happen that we did start with finance and customer service in the U.S. But for some of the other projects, particularly those affecting gross profit, we're doing that globally and not just in the U.S. So I think it just depends on the project itself. We are taking a phased approach, and we're seeing really good progress in Phase 1. We expect to start seeing more benefit in the second half of the year from that, and we'll continue to methodically work our plan to deliver on the full $200 million over the next few years.

There are no further questions at this time. I'd like to turn the floor back to Fred Lowery for closing comments.

Thank you, and thank you for your questions. And to conclude, I'd just like to maybe just a quick recap. Our second quarter results demonstrated really strong underlying double-digit earnings growth, driven by internal local currency sales growth and strong margins, combined with some initial value creation benefits, we expect this momentum to continue. We are, therefore, raising our full year 2026 guidance while maintaining a conservative and disciplined stance by excluding any additional remeasurement gains, which had previously been in our projections, thereby providing clarity to the underlying business growth. We're executing against a clear plan grounded in our strong foundation, and we expect to continue to create shareholder value through accelerating growth, simplifying our business and driving operational rigor. This includes our value creation for growth initiatives, which are on track to plan. To sum it up, we're energized by what lies ahead, and we look forward to updating you on our continued progress throughout the year. Thank you for your interest in Henry Schein, and enjoy the rest of the day.

This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.